adh4 Antibody

What is ADH4 and what biological functions does it perform in experimental models?

ADH4 encodes the class II alcohol dehydrogenase 4 pi subunit, a member of the alcohol dehydrogenase family. It functions in metabolizing diverse substrates including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. The protein exists as a homodimer composed of two pi subunits .

Unlike its family member ADH1 that provides protection against vitamin A toxicity, ADH4 plays a distinctive role in promoting survival during vitamin A deficiency, demonstrating the specialized evolutionary adaptations within this enzyme family . This differentiation is particularly important when designing nutritional deficiency studies or investigating retinoid metabolism in experimental models.

What are the recommended applications and dilutions for ADH4 antibody in laboratory research?

ADH4 antibody has been validated for multiple research applications with specific optimal dilution ranges:

It's critical to note that researchers should optimize these dilutions for their specific experimental systems to obtain optimal results . The antibody has been successfully employed in published research for both WB and IHC applications, with at least 1 publication utilizing WB and 3 publications using IHC methodologies .

Which biological samples show reactivity with ADH4 antibody in validation testing?

The ADH4 antibody (16474-1-AP) demonstrates cross-reactivity with samples from multiple species:

For IHC applications, antigen retrieval protocols have been optimized, with recommended use of TE buffer pH 9.0, although citrate buffer pH 6.0 serves as an acceptable alternative .

How does ADH4 expression differ between hepatocellular carcinoma and normal liver tissue, and what are the implications for experimental design?

ADH4 exhibits significantly lower expression in hepatocellular carcinoma (HCC) tissues compared to normal liver tissues, serving as a potential downregulated biomarker for this cancer type. This differential expression pattern extends beyond HCC to various other cancer types .

When designing experiments to investigate this expression difference, researchers should:

• Include paired tumor and adjacent non-cancerous tissue samples

• Utilize techniques such as IHC, which has demonstrated the ability to detect this differential expression

• Consider both transcriptomic approaches (RNA analysis) and protein-level analysis (Western blot/IHC)

• Incorporate statistical validations using Wilcoxon signed-rank tests and unpaired Wilcoxon rank sum tests when analyzing expression data across datasets

This downregulation pattern suggests that ADH4 may serve as a tumor suppressor in HCC, warranting experiments designed to investigate its mechanistic role in hepatocarcinogenesis.

What methods have been developed for studying ADH4 function through knockout models?

Gene targeting vectors have been successfully developed to study ADH4 function in vivo. A methodological approach for creating ADH4 knockout models involves:

• Constructing gene replacement targeting vectors (e.g., using hygromycin or neomycin selection markers)

• Employing electroporation to introduce linearized constructs into embryonic stem cells

• Using dual selection strategies (positive selection with hygromycin/neomycin and negative selection with gancyclovir)

• Verifying gene targeting through Southern blot analysis using external DNA probes

• Performing karyotype analysis before blastocyst injection

• Confirming germline transmission through coat color and subsequent genotyping

Double knockout models (e.g., ADH1/ADH4) have been successfully generated, demonstrating that ADH4 knockout mice are viable and fertile, with normal Mendelian inheritance patterns. Western blot analysis can verify the absence of ADH protein in these models . These knockout systems provide valuable tools for investigating ADH4's physiological roles, particularly in vitamin A metabolism and toxicity studies.

What is the relationship between ADH4 expression and immune cell infiltration in cancer microenvironments?

ADH4 expression correlates significantly with immune cell infiltration in the tumor microenvironment, particularly in hepatocellular carcinoma (HCC). Research has revealed several important associations:

• HCC samples with high ADH4 expression demonstrate higher proportions of neutrophils and Tcm cells

• Conversely, samples with low ADH4 expression show enrichment of TFH cells, NK CD56bright cells, and Th2 cells (p < 0.001)

• Correlation analyses reveal significant negative associations between ADH4 expression and various immune cell markers:

These findings suggest ADH4 may function as an immunoregulatory factor in HCC, highlighting its potential immunomodulatory role in the tumor microenvironment . This relationship provides rationale for investigating ADH4 as a potential target for immunotherapeutic interventions.

What are the optimal storage conditions and handling practices for maintaining ADH4 antibody efficacy?

To maintain optimal ADH4 antibody activity, researchers should adhere to the following storage and handling practices:

• Storage temperature: Store at -20°C

• Buffer composition: PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

• Stability: Antibody remains stable for one year after shipment when properly stored

• Aliquoting: Not necessary for -20°C storage

• Special considerations: 20μl size formats contain 0.1% BSA

These conditions ensure the maintenance of antibody specificity and reactivity for experimental applications over the recommended storage period.

What antigen retrieval methods are most effective for ADH4 immunohistochemistry?

For optimal ADH4 detection in immunohistochemistry applications, specific antigen retrieval protocols have been established:

• Primary recommended method: TE buffer at pH 9.0

• Alternative method: Citrate buffer at pH 6.0

The selection between these methods may depend on the specific tissue type, fixation procedures, and counterstaining techniques. Researchers should validate these protocols with appropriate positive and negative controls for their specific experimental conditions.

How can researchers validate ADH4 antibody specificity for their experimental systems?

Validation of ADH4 antibody specificity requires multiple approaches:

• Positive control selection: Use tissues/cells with known ADH4 expression, including:

  • HepG2 cells, HeLa cells (human sources)

  • Mouse brain and liver tissues

  • Rat liver tissue

• Western blot validation: Verify detection at the expected molecular weight (observed: 43 kDa; calculated: 40 kDa)

• Knockout validation: When available, utilize ADH4 knockout tissues/cells as negative controls, as demonstrated in ADH4 knockout mouse models where Western blot analysis confirmed absence of ADH4 protein

• Cross-reactivity assessment: Test antibody against samples from different species if cross-species experiments are planned

• Alternative antibody comparison: When possible, compare results with alternative ADH4 antibodies targeting different epitopes

How can ADH4 be utilized as a diagnostic and prognostic marker in hepatocellular carcinoma research?

ADH4 shows significant potential as both a diagnostic and prognostic marker for hepatocellular carcinoma (HCC) research based on several key findings:

• Diagnostic utility: ADH4 shows consistent downregulation in HCC compared to adjacent normal tissue, allowing for potential diagnostic applications

• Prognostic relevance: Low ADH4 expression correlates with:

  • Multiple clinicopathological variables associated with poor outcomes

  • Serves as an independent prognostic marker for HCC patients

• Methodological approach for evaluation:

  • Immunohistochemistry for protein-level detection in clinical samples

  • Transcriptomic analysis through qPCR or RNA-seq methodologies

  • Statistical validation using Kaplan-Meier, logistic regression and Cox analyses

• Combined biomarker strategy: Consider evaluating ADH4 alongside other candidate markers (DNASE1L3, RDH16, LCAT, HGFAC) for enhanced diagnostic and prognostic accuracy

This evidence supports incorporating ADH4 assessment in clinical HCC research studies, potentially improving patient stratification and treatment decision algorithms.

What is the potential of ADH4 as a target for immunotherapy development research?

ADH4 demonstrates several characteristics that suggest potential as an immunotherapeutic target:

• Immune microenvironment interactions: ADH4 expression correlates with immune cell infiltration patterns in HCC, including associations with:

  • Neutrophils and Tcm cells (positive correlation with high ADH4)

  • TFH cells, NK CD56bright cells, and Th2 cells (negative correlation)

• TME-specific expression: The low expression pattern of ADH4 appears to be tumor microenvironment (TME)-specific, suggesting potential for targeted therapeutic approaches

• Correlation with immune cell markers: Significant negative correlations with markers of various immune cell populations (B cells, macrophages, neutrophils, and dendritic cells) indicate potential for modulating tumor immune responses

• Validation methodology: IHC confirmation of CD68, CD4, and CD19 protein levels in HCC tissues provides supporting evidence for ADH4's role in immune modulation

These findings suggest that researchers developing immunotherapeutic strategies should consider ADH4 as a candidate target, particularly for approaches aimed at modifying the immune microenvironment in HCC.

What approaches can resolve weak or inconsistent ADH4 detection in immunohistochemistry applications?

When facing challenges with ADH4 detection in IHC, researchers should consider these methodological optimizations:

• Antigen retrieval modification:

  • Primary recommendation: Test TE buffer pH 9.0

  • Alternative approach: Switch to citrate buffer pH 6.0

  • Consider extending retrieval time for heavily fixed samples

• Antibody dilution optimization:

  • Begin with the recommended 1:50-1:500 range

  • Conduct a dilution series to determine optimal concentration for specific tissue types

  • For weak signals, try the more concentrated end of the range (1:50)

• Detection system enhancement:

  • Consider amplification systems for low-abundance targets

  • Evaluate alternative chromogens if background interference is problematic

  • Extend development time while monitoring for optimal signal-to-noise ratio

• Sample preparation considerations:

  • Evaluate fixation protocols (duration, fixative type)

  • Optimize section thickness (4-6μm typically optimal)

  • Ensure consistent tissue processing across experimental and control samples

• Positive control inclusion:

  • Always run validated positive controls (human kidney or heart tissue)

  • Include tissues with known high ADH4 expression as internal standards

Systematic application of these troubleshooting approaches should resolve most issues with ADH4 detection in IHC applications.

How can researchers address cross-reactivity and specificity challenges when using ADH4 antibody across different experimental systems?

To optimize ADH4 antibody specificity across diverse experimental systems:

• Species-specific considerations:

  • Confirmed reactivity: Human, mouse, and rat samples

  • When working with unvalidated species, perform preliminary validation studies

  • Consider sequence homology analysis to predict potential cross-reactivity

• Blocking optimization:

  • Test different blocking reagents (BSA, normal serum, commercial blockers)

  • Extend blocking time for tissues with high background

  • Evaluate concentration-dependent effects of blocking reagents

• Antibody validation approaches:

  • Western blot confirmation of specificity at expected molecular weight (43 kDa)

  • Peptide competition assays to confirm binding specificity

  • Knockout/knockdown validation when available

• Application-specific optimizations:

  • Western blot: Optimize transfer conditions for ADH4's molecular weight

  • IHC: Adjust fixation and antigen retrieval for specific tissue types

  • Consider the impact of protein post-translational modifications on antibody recognition

• Experimental design considerations:

  • Include technical replicates to assess consistency

  • Incorporate biological replicates to account for natural variation

  • Document lot-to-lot variations in antibody performance

These strategies promote reliable, reproducible results when working with ADH4 antibody across diverse experimental systems.